INS and Hypoglycemia: IDeg provides substantial reductions in glycosylated haemoglobin (HbA1c) with low rates of overall and nocturnal hypoglycaemia, and is the only basal insulin with the potential of being dosed at any time of day with the possibility of changing injection time in response to changes in patients’ daily schedules, without compromising efficacy or safety 12–15.